<DOC>
	<DOC>NCT02436239</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).</brief_summary>
	<brief_title>A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Male or Female outpatients betw een 717 years of age Primary diagnosis of major depressive disorder (MDD) Children's Depression Rating ScaleRevised (CDRSR) score of 40 or greater Clinical Global ImpressionsSeverity (CGIS) score of 4 or greater Current (past 3 months) principal Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision based diagnosis of an Axis I disorder other than MDD that is the primary focus of treatment (de novo patients only) History of suicidal behavior, or requires precaution against suicide Not generally healthy medical condition Seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>